Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (RNA) has granted equity-based inducement awards to 16 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards include 71,000 non-qualified stock options with an exercise price of $31.64 per share and 35,000 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. All awards are subject to continued employment and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for joining the company.
Avidity Biosciences (RNA) ha concesso premi azionari a 16 nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivi per l'Assunzione 2022. I premi includono 71.000 opzioni su azioni non qualificate con un prezzo di esercizio di 31,64 $ per azione e 35.000 unità azionarie vincolate (RSU).
Le opzioni su azioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi. Le RSU matureranno in quattro rate annuali uguali. Tutti i premi sono subordinati alla continuità lavorativa e sono stati concessi in conformità alla Regola Nasdaq 5635(c)(4) come incentivo per l'ingresso in azienda.
Avidity Biosciences (RNA) ha otorgado premios basados en acciones a 16 nuevos empleados no ejecutivos bajo su Plan de Incentivos de Contratación 2022. Los premios incluyen 71,000 opciones sobre acciones no calificadas con un precio de ejercicio de $31.64 por acción y 35,000 unidades restringidas de acciones (RSU).
Las opciones sobre acciones se consolidarán durante cuatro años, con un 25% consolidado después de un año y el resto consolidado mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en cuatro cuotas anuales iguales. Todos los premios están sujetos a la continuidad laboral y se otorgaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivos para unirse a la empresa.
Avidity Biosciences (RNA)는 2022년 고용 유인 인센티브 계획에 따라 16명의 신규 비임원 직원에게 주식 기반 인센티브를 부여했습니다. 이 인센티브에는 71,000개의 비공인 주식 매수 선택권이 포함되며, 행사가격은 주당 31.64달러이고, 35,000개의 제한 주식 단위(RSU)도 포함되어 있습니다.
주식 매수 선택권은 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 부여되고 나머지는 36개월 동안 매월 부여됩니다. RSU는 4년간 매년 동일한 비율로 부여됩니다. 모든 인센티브는 계속 근무 조건이 충족되어야 하며, 나스닥 상장 규칙 5635(c)(4)에 따라 입사 유인책으로 부여되었습니다.
Avidity Biosciences (RNA) a accordé des primes en actions à 16 nouveaux employés non cadres dans le cadre de son plan d'incitation à l'embauche 2022. Ces primes comprennent 71 000 options d'achat d'actions non qualifiées avec un prix d'exercice de 31,64 $ par action et 35 000 unités d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises en quatre versements annuels égaux. Toutes les primes sont soumises à la poursuite de l'emploi et ont été accordées conformément à la règle Nasdaq 5635(c)(4) en tant qu'incitations à rejoindre l'entreprise.
Avidity Biosciences (RNA) hat 16 neuen nicht geschäftsführenden Mitarbeitern im Rahmen seines Anreizplans für Neueinstellungen 2022 aktienbasierte Zuwendungen gewährt. Die Zuwendungen umfassen 71.000 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 31,64 $ pro Aktie sowie 35.000 Restricted Stock Units (RSUs).
Die Aktienoptionen werden über vier Jahre vesten, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate vesten. Die RSUs vesten in vier gleichen jährlichen Tranchen. Alle Zuwendungen unterliegen der fortlaufenden Beschäftigung und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für den Eintritt in das Unternehmen gewährt.
- None.
- None.
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Avidity, pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302462257.html
SOURCE Avidity Biosciences, Inc.
FAQ
What equity awards did Avidity Biosciences (RNA) grant to new employees in May 2025?
What is the vesting schedule for RNA's May 2025 inducement stock options?
How do the RSUs vest in Avidity Biosciences' May 2025 inducement grants?
What is the exercise price for RNA's May 2025 inducement stock options?
